12:00 AM
 | 
Aug 19, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Kyprolis carfilzomib regulatory update

Onyx partnered with Idis Ltd. (Weybridge, U.K.) to launch a managed access program to provide patients in certain European countries access to carfilzomib to treat patients with multiple myeloma (MM) who received >=2 prior lines of therapy, including bortezomib and an immunomodulatory agent,...

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >